Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas
This article was originally published in The Pink Sheet Daily
Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.
You may also be interested in...
Optimer Pharmaceuticals’ antibiotic Dificid is on track to exceed one-year targets agreed upon with co-promotion partner Cubist.
A year after FDA approval of its antibiotic Dificid, the Optimer board has ousted its chairman and at least two other top executives.
EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.